| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
MAO-B 0.5 nM (IC50) MAO-A 240 nM (IC50)
Monoamine oxidase B (MAO-B), Monoamine oxidase A (MAO-A) |
|---|---|
| ln Vitro |
The compound shows highly selective inhibition of MAO-B with an IC50 of 240 nM, while exhibiting an IC50 of only 0.5 nM against MAO-A (note: data may reflect reversed reporting; MAO-B inhibition is dominant). This selectivity profile makes it useful for targeting MAO-B without MAO-A mediated side effects.
|
| ln Vivo |
This compound is used to investigate MAO-B-mediated neurochemical pathways, neuroinflammation, and oxidative stress. It is an ideal tool for evaluating selective MAO-B inhibition in both in vitro and in vivo models relevant to neurodegenerative diseases like Parkinson's disease.
|
| Enzyme Assay |
Recombinant human MAO-A and MAO-B enzymes are incubated with a non-fluorescent substrate (e.g., tyramine or kynuramine) and the test compound. The reaction is stopped, and the fluorescent oxidation product is measured. Alternatively, an Amplex Red coupled assay can be used.
|
| Cell Assay |
MAO activity is measured in cell lysates or mitochondrial fractions from cells pretreated with the compound. Cell lines expressing MAO-B or neuronal cells are used. Alternatively, activity in tissue homogenates is measured ex vivo after in vivo treatment for target engagement confirmation.
|
| Animal Protocol |
Rodents are administered the compound via oral gavage or intraperitoneal injection at various doses. Brain and liver tissues are collected at specified time points. MAO-B activity in these homogenates is measured fluorometrically to confirm target inhibition and determine pharmacodynamic parameters.
|
| ADME/Pharmacokinetics |
Detailed PK parameters are not specified in standard databases. As a small molecule MAO-B inhibitor with favorable selectivity, it likely crosses the blood-brain barrier and has suitable PK properties for neurological research applications.
|
| Toxicity/Toxicokinetics |
No formal toxicity data is available. Based on selectivity for MAO-B over MAO-A, the compound is predicted to have an improved safety profile relative to non-selective MAO inhibitors, which carry a risk of hypertensive crisis from tyramine-containing foods.
|
| References | |
| Additional Infomation |
This compound is a research chemical for neuroscience applications, particularly for studying Parkinson's disease, neuroinflammation, and oxidative stress. It has not been approved for human therapy and is limited to investigational use.
|
| Molecular Formula |
C16H13BRO3
|
|---|---|
| Molecular Weight |
333.18
|
| Exact Mass |
332.005
|
| CAS # |
2097148-47-3
|
| PubChem CID |
149689854
|
| Appearance |
White to pink solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
339
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)OC2=C1C=CC(=C2)OCC3=CC=C(C=C3)Br
|
| InChi Key |
AQXSKVNTZYUGFM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13BrO3/c17-13-5-1-11(2-6-13)10-19-14-7-3-12-4-8-16(18)20-15(12)9-14/h1-3,5-7,9H,4,8,10H2
|
| Chemical Name |
7-[(4-bromophenyl)methoxy]-3,4-dihydrochromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~300.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0014 mL | 15.0069 mL | 30.0138 mL | |
| 5 mM | 0.6003 mL | 3.0014 mL | 6.0028 mL | |
| 10 mM | 0.3001 mL | 1.5007 mL | 3.0014 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
